Please use this identifier to cite or link to this item: https://hdl.handle.net/2440/9179
Citations
Scopus Web of Science® Altmetric
?
?
Full metadata record
DC FieldValueLanguage
dc.contributor.authorQuan, C.-
dc.contributor.authorTalley, N.-
dc.contributor.authorCross, S.-
dc.contributor.authorJones, M.-
dc.contributor.authorHammer, J.-
dc.contributor.authorGiles, N.-
dc.contributor.authorHorowitz, M.-
dc.date.issued2003-
dc.identifier.citationAlimentary Pharmacology and Therapeutics, 2003; 17(9):1179-1187-
dc.identifier.issn0269-2813-
dc.identifier.issn1365-2036-
dc.identifier.urihttp://hdl.handle.net/2440/9179-
dc.descriptionThe definitive version is available at www.blackwell-synergy.com Article first published online: 2 MAY 2003-
dc.description.abstractBackground: Although gastrointestinal symptoms occur frequently, there is no validated measure of gastrointestinal symptoms in patients with diabetes mellitus. Aim: To develop the Diabetes Bowel Symptom Questionnaire. Methods: A questionnaire derived from previously validated symptom measures was compiled to assess all relevant gastrointestinal and diabetes items. Face and content validity were ascertained by expert review. One hundred and sixty-eight patients with diabetes mellitus completed the instrument, and reliability was evaluated by a test–re-test procedure 1 week later. Concurrent validity was evaluated by an independent physician interview (n = 33). Measures of glycaemic control (glycated haemoglobin and plasma glucose) were compared with self-reported glycaemic control on a five-point Likert scale in diabetic out-patients (n = 166). Results: The questionnaire had adequate face and content validity. There was good to excellent test–re-test reliability for the gastrointestinal and diabetes items (median kappa: 0.63 and 0.79, respectively); concurrent validity was good to excellent (median kappa: 0.47 and 0.65, respectively), except for the items assessing the severity of gastrointestinal symptoms. Both glycated haemoglobin (P < 0.0001) and plasma glucose (P = 0.005) correlated significantly with self-reported glycaemic control. Conclusion: The Diabetes Bowel Symptom Questionnaire appears to be a useful measure of gastrointestinal symptoms and glycaemic control in diabetes mellitus, and should have applicability in epidemiological and clinical studies.-
dc.description.statementofresponsibilityC. Quan, N. J. Talley, S. Cross, M. Jones, J. Hammer, N. Giles & M. Horowitz-
dc.language.isoen-
dc.publisherBlackwell Science Ltd-
dc.rights© 2003 Blackwell Publishing Ltd-
dc.source.urihttp://dx.doi.org/10.1046/j.1365-2036.2003.01553.x-
dc.subjectHumans-
dc.subjectGastrointestinal Diseases-
dc.subjectDiabetes Complications-
dc.subjectSensitivity and Specificity-
dc.subjectReproducibility of Results-
dc.subjectAdult-
dc.subjectAged-
dc.subjectMiddle Aged-
dc.subjectFemale-
dc.subjectMale-
dc.subjectSurveys and Questionnaires-
dc.titleDevelopment and validation of the Diabetes Bowel Symptom Questionnaire-
dc.typeJournal article-
dc.identifier.doi10.1046/j.1365-2036.2003.01553-
pubs.publication-statusPublished-
dc.identifier.orcidHorowitz, M. [0000-0002-0942-0306]-
Appears in Collections:Aurora harvest 4
Medicine publications

Files in This Item:
There are no files associated with this item.


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.